Working with partners
Find out about the ways we work in partnership with other organisations to establish a research system in the UK that meets the needs of all those involved.
Key collaborations
Accelerated Access Collaborative
A partnership between patient groups, government bodies, industry and NHS organisations. Members work together to streamline the adoption of new innovations in healthcare.
Innovation Observatory
National medical horizon scanning facility. The observatory keeps an eye on future medicines, devices and diagnostics. Its work helps shape policy, regulation, approvals and stimulates research activity.
Innovations in Clinical Trial Design and Delivery for the Under-served
A project to make research more inclusive and better involve under-served groups.
Support for industry partners
Collaboration with industry
Details of the support the NIHR can provide life sciences and MedTech organisations. This includes funding opportunities, access to specialist facilities and help setting up studies.
Study Support Service for Industry
The NIHR offers life sciences organisations free support to help plan, place and perform high quality clinical research in the UK.
Support for other partners
Local Authorities
Details of how the NIHR works with local authorities and councils across the UK. Research aims to improve health and wellbeing, support independence and reduce health inequalities.
Working with charities
The NIHR partners with health and social care charities to support research. Charity partnerships combine expertise, streamline processes and bring benefits to patients and the public faster.
Working with other funders
Details of how the NIHR works with other funders of health and care research in the UK, including UK research councils and government bodies.
Improving outcomes in cystic fibrosis with inhaled gene therapy
Read how a research trial of inhaled gene therapy stabilised lung function in patients with cystic fibrosis. Evidence from the trial has contributed to a partnership between researchers and commercial companies to develop clinical trials and a potential treatment for cystic fibrosis.
